Efficacy And Safety Of Abp 798 Compared With Rituximab: Results From The Comparative Clinical Study In Patients With Non-Hodgkin'S.

Dietger Niederwieser,Caroline M. Hamm,Patrick Cobb,Mindy Mo,Cecily Forsyth,Alessandra Tucci,Vladimir Hanes,Vincent Delwail,Roman Hajek,David Chien

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 0|浏览0

暂无评分

摘要

8044Background: ABP 798* is being developed as a biosimilar to rituximab, a CD20-directed cytolytic antibody. A randomized, double-blind, active-controlled study compared the efficacy, safety, and ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要